BioCentury
ARTICLE | Clinical News

Nimotuzumab: Completed Phase II enrollment

February 21, 2011 8:00 AM UTC

YM BioSciences disclosed in its fiscal 2Q11 earnings that partner Daiichi Sankyo completed enrollment in a Phase II trial evaluating nimotuzumab in combination with radiation therapy, cisplatin and vi...